The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Recent studies suggest that some misunderstanding around lead-time bias continues to persist in the literature.
In Mendelian randomization analyses, increase in genetically predicted IGF-1 linked to breast cancer.
In this study, nurse participants emphasized the connection between the early delivery of prognostic information and the optimal delivery of palliative care.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Increase began before secular decrease in parity and cannot be attributed to changes in parity over time.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Results of earlier-phase trials provided support for this phase 3 trial in triple-negative, stage II/III breast cancer.
Common concerns among employed respondents include increased time off, suffering job performance.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
The adaptive design of the I-SPY2 study allowed for the rapid evaluation of novel drugs in combination with neoadjuvant chemotherapy (NAC) compared with NAC alone.
No significant reductions found in eight-year breast cancer mortality for continuing versus stopping screening.
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Survival benefits were maintained among those with brain metastases.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
BMI had no impact on progression-free survival to first-line chemotherapy.